Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
NPC Blog
NPC Blog
2010 Archives
2009 Archives
2008 Archives
2007 Archives
2006 Archives
Search Archives
Archives
  • December 2012 (3)
  • November 2012 (1)
  • October 2012 (1)
  • May 2012 (1)
  • December 2011 (1)
  • November 2011 (3)
  • October 2011 (4)
  • September 2011 (4)
  • August 2011 (6)
  • July 2011 (13)
  • June 2011 (8)
  • May 2011 (10)
  • April 2011 (14)
  • March 2011 (6)
  • February 2011 (2)
  • February 2010 (4)
  • January 2010 (1)
  • December 2009 (1)
  • November 2009 (1)
  • October 2009 (1)
  • September 2009 (2)
  • July 2009 (1)
  • April 2009 (1)
  • March 2009 (1)
  • February 2009 (1)
  • December 2008 (1)
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)
  •  

    Subscribe in a reader

    E-Alerts
    Signup to receive news and announcements from Nutra Pharma:
    First Name:
    Last Name:
    Email:
     
    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

    NPC Blog

    Our Focus on Adrenomyeloneuropathy (AMN)

    Adrenomyeloneuropathy (AMN) is a rare hereditary disease that affects approximately 30,000 people worldwide. Even though most people have never heard of AMN, it continues to be a very important focus for Nutra Pharma’s drug development.

    Our goal is to receive the approval to launch the first-ever treatment for AMN using our lead drug candidate for autoimmune and neurological disorders, RPI-78M. Almost a year and a half ago, we began a 15-month phase IIb/IIIa human clinical trial in London to help us better understand the efficacy of RPI-78M in treating AMN. Because patients started the trial at different times (we refer to this as a staggered start), the trial is now coming to a close.

    One of the primary reasons we chose to focus on AMN is because its symptoms display very similar characteristics to those of Multiple Sclerosis (MS). Many who have followed Nutra Pharma over the years already know that we are researching a possible treatment for MS. Both AMN and MS are characterized by demyelination, or, the loss of the myelin sheath insulating the nerves.

    Our previous clinical trial data has led us to believe that RPI-78M induces gamma-interferon and interleukin-27 (IL-27). Recently, IL-27 was discovered to be an important anti-inflammatory regulator in cells of the immune system and many scientists now believe that IL-27 helps reduce symptoms of MS. We feel this property is not isolated to MS, but extends into AMN as well.

    As a side note, we filed a patent with the United States Patent office in April 2007 to protect our method of regulating IL-27 using modified cobratoxin.

    Because we are just now completing our phase IIb/IIIa clinical trial for the treatment of AMN, we expect to have the data compiled by mid to late August. Once we finish reviewing this data, it will be released to the public and our shareholders.

    In the meantime, here are some additional resources for learning more about Adrenomyeloneuropathy:

    AMNhelp.com
    An online resource published by Nutra Pharma about AMN

    AMN Community on RareShare
    An online community for people affected by AMN

    United Leukodystrophy Foundation
    A foundation dedicated to helping children and adults who have Leukodystrophy and assisting the family members, professionals and support services that serve them.


    SEC Disclaimer
    This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Our Focus on Adrenomyeloneuropathy (AMN)", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

    del.icio.us:Our Focus on Adrenomyeloneuropathy (AMN) digg:Our Focus on Adrenomyeloneuropathy (AMN) spurl:Our Focus on Adrenomyeloneuropathy (AMN) wists:Our Focus on Adrenomyeloneuropathy (AMN) simpy:Our Focus on Adrenomyeloneuropathy (AMN) newsvine:Our Focus on Adrenomyeloneuropathy (AMN) blinklist:Our Focus on Adrenomyeloneuropathy (AMN) furl:Our Focus on Adrenomyeloneuropathy (AMN) reddit:Our Focus on Adrenomyeloneuropathy (AMN) fark:Our Focus on Adrenomyeloneuropathy (AMN) blogmarks:Our Focus on Adrenomyeloneuropathy (AMN) Y!:Our Focus on Adrenomyeloneuropathy (AMN) smarking:Our Focus on Adrenomyeloneuropathy (AMN) magnolia:Our Focus on Adrenomyeloneuropathy (AMN) segnalo:Our Focus on Adrenomyeloneuropathy (AMN) gifttagging:Our Focus on Adrenomyeloneuropathy (AMN)


    Comments

    No comments yet.

    RSS feed for comments on this post.

    TrackBack URL


    Leave a Comment

     
    Quick Nav
    Nyloxin // Chronic Pain Relief
    Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
     

     

     
    Recent News
     
    January 07, 2014
    Nutra Pharma Announces the First Shipments and Product Delivery to MyNyloxin.com Independent Entrepreneurs


    December 02, 2013
    Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin


    November 11, 2013
    Nutra Pharma Provides Updates for the Marketing of Its All-Natural Pain Reliever, Nyloxin®


     
     
    Announcements
    Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
     
     
    Facebook   Twitter
     
    NPC
    Privacy Policy Code of Ethics